As of 2025-12-18, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 16.2x | 15.2x |
| Forward P/E multiples | 19.2x - 43.2x | 30.7x |
| Fair Price | (125.91) - (105.60) | (151.47) |
| Upside | -265.6% - -238.9% | -299.3% |
| Date | EV/EBITDA |